2021 AABB Annual Meeting On-Demand

Oct 17, 2021 ‐ Oct 19, 2021


Access to the 2021 AABB Annual Meeting On-Demand sessions expires on December 31, 2023. Each session includes the on-demand recording and a downloadable MP3 audio file. Closed captioning in Spanish and English also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.



Sessions

AM21-22: How to Handle Challenging Apheresis Consults

Oct 18, 2021 10:00am ‐ Oct 18, 2021 11:00am

Credits: None available.

Therapeutic apheresis is used to treat various types of disorders. The American Society for Apheresis (ASFA) publishes evidence-based guidelines every 3 years to assist apheresis practitioners in the rationale and management of apheresis patients and outlines basic technical specifications for procedures. However, the guidelines provide limited guidance on the urgency of the procedures and only comment on indications with enough published evidence available for categorization. In this session, a summary of the ASFA guidelines and a review of how to perform an apheresis consult will be presented. This session will then discuss how to approach consults with a clinical team, when the indication for a procedure is beyond the ASFA guidelines. Furthermore, the session will address the ethical and legal challenges for these discussions and decisions.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Summarize how to approach an apheresis consult, including urgency of the procedure
  • Review examples of challenge issues in rejecting an apheresis request
  • Discuss the potential ethical and legal ramification in apheresis medicine
Moderator(s): Speaker(s): Disclosures
  • Jaye Barbeau, MD, JD : Nothing to Disclose
  • Joseph Schwartz, MD, MPH : Consultant: Gamida Cell; Plass-Free, Argen X
  • Huy Pham, MD, MPH : Consultant: Sanofi; Honoraria: Argenx; Royalty: Elsevier
Members: $20.00
Standard: $25.00

AM21-23: Creating the Blood Center Infrastructure for Biotherapies: From Contracts to Collections and Distribution

Oct 18, 2021 10:00am ‐ Oct 18, 2021 11:00am

Credits: None available.

Blood Banks and Blood Centers (BB/BC) are playing a key role in the advancement of cell and biotherapies. BB/BC are working with pharmaceutical companies as our community advances these therapies to enhance the quality and safety of patient care. This demand necessitates infrastructure development at BB/BC. In this session the speakers will share experiences from 2 BB/BC. They will share their experiences including (1) contracts and budgets, (2) developing pricing, (3) information technology (IT) needs and challenges for Blood Establishment Computer System (BECS) tracking to integrating International Society of Blood Transfusion (ISBT) requirements and (4) how to track and handle compliance among different companies.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify infrastructure needs for Blood Banks and Blood Centers (BB/BC) to develop a cell and biotherapy program.
  • Describe actions to overcome some of the challenges faced by BB/BC
  • List key items for developing a budget in a contract with a pharmaceutical company
Moderator(s):
  • Dr. Gay Wehrli, MD, MBA, MSEd, University Hospitals, Samaritan Medical Center and Case Western
Speaker(s): Disclosures
  • Manlio Narici, MBA : Nothing to Disclose
  • David Wellis, PhD : Nothing to Disclose
  • Gay Wehrli, MD, MBA, MSEd : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-24: Hot Topic: Men Who Have Sex with Men (MSM): Movement Toward Individual Risk Assessment

Oct 18, 2021 11:15am ‐ Oct 18, 2021 12:15pm

Credits: None available.

The US MSM deferral was reduced from “if even one time since 1977” in 2018 to 12 months, and in 2020 3 months. A few countries such as Italy and Spain have alternative criteria (no MSM deferral). In France and Israel MSM donate plasma with quarantine. In December 2020 a group supported by the Forum representing the four UK blood services “For the Assessment of Individual Risk (FAIR)” reported that a more individualized approach to donor selection policy was feasible in the UK. This was accepted by health ministers and is expected to be implemented in the summer of 2021. In the US, the Assessing Donor Variability And New Concepts in Eligibility (ADVANCE Study), a pilot study to evaluate behavioral screening questions is in progress. Sponsored by the AABB Donor History Task Force and the ISBT Transfusion Transmitted Infectious Diseases Working Party this session will focus on imminent changes to donor eligibility for MSM in the UK and progress towards revised donor criteria in the US.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Examine the UK’s alternative donor criteria to assess risk previously addressed with the MSM time deferral.
  • Explain the rationale behind the selection of the above donor criteria
  • Discuss the research in progress in the US to evaluate potential alternative criteria to MSM time-based deferral
Moderator(s): Speaker(s): Disclosures
  • Sheila O'Brien, PhD : Nothing to Disclose
  • Katy Davison, MPH : Nothing to Disclose
  • Brian Custer, PhD. MPH : Grant Grifols Diagnostic Solutions
Members: $20.00
Standard: $25.00

AM21-25: New Insights and Drug Development for Ineffective Erythropoiesis in Thalassemia and Sickle Cell Disease

Oct 18, 2021 11:15am ‐ Oct 18, 2021 12:15pm

Credits: None available.

Red cell transfusion has been a mainstay in treatment of both beta-thalassemia and sickle cell disease, but recent research is further exploring the role for ineffective erythropoiesis not only in thalassemia but also in sickle cell disease. Dr. Wassim El Nemer will describe the mechanisms for ineffective erythropoiesis in sickle cell disease, and its implications for treatment with hydroxyurea, voxelotor, and gene therapy. Dr. Yelena Ginzburg will discuss new insights into ineffective erythropoiesis in beta-thalassemia, and the role of newly approved activin II receptor traps as well as other emerging therapies, such as JAK2 inhibitors and hepcidin mimetics.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify new research findings regarding ineffective erythropoiesis in thalassemia and sickle cell disease.
  • Assess the implications of these findings for treatment of these two diseases.
  • Explain mechanisms of action against ineffective erythropoiesis with current and emerging therapies.
Moderator(s): Speaker(s): Disclosures
  • Wassim El Nemer, PhD : Nothing to Disclose
  • Yelena Ginzburg, MD : Consultant: Protagonist Therapeutics, Ionis Pharmaceuticals; Grant/Research Support: Protagonist Therapeutics
  • Patricia Shi, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-26: Ethics of Engaging Blood Donors for Cell Therapy (Biotherapy) Collections

Oct 18, 2021 11:15am ‐ Oct 18, 2021 12:15pm

Credits: None available.

The need for cell and biotherapy donors is rising. To help meet this demand, blood centers are working to transition regular blood donors to become cell and biotherapy donors. Human subject protection is an important aspect for the donations. In this session some of the ethical challenges related to this recruitment and process will be presented and discussed. Topics include biotherapy donor informed consent, payment and frequency of donation. An ethicist will lead this discussion for a robust question and answer period.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify key informed consent issues such as sharing with the donor what happens with the cells collected, when this is of a proprietary nature.
  • Recognize the challenges in explaining and justifying why these donors are paid versus other blood donors. Will we lose blood donors?
  • Examine and describe the concerns for repeat biotherapy donations.
Moderator(s):
  • Dr. Gay Wehrli, MD, MBA, MSEd, University Hospitals, Samaritan Medical Center and Case Western
Speaker(s): Disclosures
  • Jamie Watson, PhD, HEC-C : Nothing to Disclose
  • Laurie Sutor, MD, MBA : Nothing to Disclose
  • Gay Wehrli, MD, MBA, MSEd : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-27: Updates in Intrauterine and Manual Red Cell Exchange Transfusion Practice

Oct 18, 2021 2:30pm ‐ Oct 18, 2021 3:30pm

Credits: None available.

With a decline in incidence of hemolytic disease of the fetus and newborn as well as treatment with intravenous immune globulin and phototherapy, manual exchange in neonates and intrauterine transfusion have become uncommon. This session describes practices for not only ordering and preparing blood products for these rare procedures, but also how they are performed. The results of Vox Sanguinis International Forum on the Selection and Preparation of Blood Components for Intrauterine Transfusion published in 2020 will be reviewed. Participants will be updated on current indications, blood sample testing, blood product selection/preparation, calculations for dosing, and transfusion monitoring/documentation for intrauterine transfusion. For manual exchange transfusion, discussion will include procedure technique using push/pull versus continuous infusion methods, dosing/ordering, and blood component preparation.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Name the most common indications for intrauterine transfusion
  • List attributes considered when selecting blood products for intrauterine and infant manual exchange transfusion
  • Describe the process of manual exchange transfusion in an infant
Moderator(s): Speaker(s): Disclosures
  • Gwen Clarke, MD, FRCPC : Nothing to Disclose
  • Nabiha Saifee, MD, PhD : Nothing to Disclose
  • Marie Steiner, MD : HealthCore/NERI: DSMB, PumpKIN trial
Members: $20.00
Standard: $25.00

AM21-28: Oral Abstract Session -- Blood Product Manufacturing and Storage

Oct 18, 2021 2:30pm ‐ Oct 18, 2021 3:30pm

Credits: None available.

Oral abstract session focused on blood product manufacturing and storage.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Discuss a potential for risk from donors on "therapeutic" testosterone.
  • Review how a mouse model of G6PD can be used to do physiological experiments, beyond those in patient samples
  • Consider the functionality cord blood cells as source autologous RBC transfusion in neonate transplants.
  • Compare the various novel RBC anticoagulant-preservative solutions in the use of metabolomics on a high throughput platform.
Moderator(s): Speaker(s): Disclosures
  • Jed Gorlin, MD, MBA : Nothing to Disclose
  • Thomas Klei : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-29: Hot Topic: Cryopreservation of HPCs During a Pandemic

Oct 18, 2021 2:30pm ‐ Oct 18, 2021 3:30pm

Credits: None available.

During this session, attendees will receive an update on current trends in using cryopreservation to support hematopoietic cell transplant (HCT) during a pandemic and a donor registry’s experience in providing centralized cryopreservation services. The speakers will also provide a brief review of the most recent studies on the use of cryopreserved allogeneic grafts.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify current cryopreservation trends for supporting unrelated HCT.
  • Describe the most recent and relevant studies looking at the use of cryopreserved allogeneic grafts.
  • Evaluate current practices when using cryopreserved allogeneic grafts across multiple transplant centers.
Speaker(s): Disclosures
  • Jeff Wren : Nothing to Disclose
  • Stephen Spellman : Nothing to Disclose
  • David McKenna, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-30: Leading the Way in a Time of Transformation - Experiences from the Armed Services Blood Program

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

The Armed Services Blood Program (ASBP) is the official blood program of the United States Department of Defense and provides support to the Military Healthcare System worldwide. This session will provide an overview of the activities that have been conducted over the past year to support the nation’s response to COVID-19 in parallel with efforts to move toward a more standardized blood program. Military leaders within the blood program will also provide an update on current research and development efforts as well as a recap on the progression of the Donor Prescreening and Walking Blood Bank program. The session will close with the Lifetime Achievement Award ceremony, which honors an awardee for lifelong, transformative contributions to the ASBP.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Summarize program activities and operations during the COVID-19 pandemic coupled with a time of unprecedented reform within the Military Health System.
  • Review the current research and development efforts and highlight the progression of donor prescreening and walking blood bank efforts to support the warfighter.
  • Identify opportunities to build a more integrated blood program through the transformation process.
Moderator & Speaker(s): Speaker(s): Disclosures
  • George Hestilow : Nothing to Disclose
  • Audra Taylor, SBB(ASCP) : Nothing to Disclose
  • Jason Corley, MS, MT(ASCP)SBB : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-31: Overcoming Inventory Management Hurdles in a Rural Versus Urban Transfusion Service

Oct 18, 2021 3:45pm ‐ Oct 18, 2021 4:45pm

Credits: None available.

Maintaining adequate blood supply to support patient needs is a critical responsibility of hospital Transfusion Services. Inventory management is a challenge because supply and demand are unpredictable, made worse recently by a pandemic, wildfires, and social unrest. In addition to threats to the inventory, another challenge is the increasing variety of products such as the 9 platelet options provided by the Food and Drug Administration Guidance, “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion.” This session will provide strategies for inventory management of red blood cells, platelets, plasma and cryoprecipitate and compare approaches suitable for Transfusion Services 1) during different levels of shortage 2) in rural versus urban settings 3) that serve different patient populations and clinical services 4) with and without a donor center.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Compare approaches for routine inventory management of red blood cells, platelets, plasma and cryoprecipitate for transfusion services in different practice settings
  • Discuss general strategies for inventory management of red blood cells, platelets, plasma and cryoprecipitate during supply challenges
  • Recognize the risks and describe plans at different centers for managing multiple types of platelet products (e.g., large volume delayed sampling, pathogen reduced, platelet additive solution) with different allowable product shelf-lives.
Moderator(s):
  • Dr. Nancy M. Dunbar, MD, Associate Professor for the Dept. of Pathology and Lab Medicine; Associate Medical Director of Transfusion Service and Medical Director of Blood Bank, Dartmouth Health
Speaker(s):
  • Reggie Thomasson, MD, Medical Director of Blood Bank and Transfusion Medicine, Assistant Professor of Pathology and Laboratory Medicine, Boston Medical Center
  • Jenna Khan, MD, Dartmouth-Hitchcock Medical Center
Disclosures
  • Reggie Thomasson, MD : Nothing to Disclose
  • Nancy Dunbar, MD : Consultant, Honoraria: Verax Biomedical
  • Jenna Khan, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00